- Home
- SGLY vs TIVC Comparison
SGLY vs TIVC Comparison
Compare SGLY & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGLY | TIVC |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.6M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SGLY | TIVC |
|---|---|---|
| Price | $0.40 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.7K | ★ 222.5K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,813,193.00 | $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.75 |
| 52 Week High | $1.45 | $5.60 |
Technical Indicators
Market Signals| Indicator | SGLY | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 69.31 |
| Support Level | $0.37 | $0.79 |
| Resistance Level | $0.43 | $2.70 |
| Average True Range (ATR) | 0.03 | 0.11 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 36.64 | 100.00 |
Price Performance
Historical ComparisonAbout SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.